Story
Braveheart Bio Aims for $1.2 Billion Valuation in Nasdaq IPO
Clinical-stage biopharmaceutical company Braveheart Bio is targeting a valuation of up to $1.2 billion in its U.S. initial public offering, according to a regulatory filing on Thursday. The company aims to raise as much as $318.8 million to advance its pipeline of cardiovascular disease treatments.
Offering Details
The San Francisco-based firm plans to offer 18.8 million shares at a price range of $15 to $17 each, the filing stated. Braveheart Bio intends to list its shares on the Nasdaq Global Market under the ticker symbol "BRVE".
Cornerstone investor Fidelity Management & Research has indicated non-binding interest in purchasing up to $75 million worth of shares in the offering. The joint bookrunners for the IPO include Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.
Focus on Heart Disease
Braveheart Bio specializes in developing novel therapeutics for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens abnormally, impairing its ability to pump blood effectively. The company plans to use the net proceeds to fund the clinical development of its lead product candidate, BHB-1893.
AdBHB-1893 is an oral cardiac myosin inhibitor designed to treat both obstructive and non-obstructive forms of HCM. Remaining funds will be allocated to further research and development, as well as general corporate purposes.
Market Context and Backing
The proposed offering comes amid a reported comeback for biotechnology IPOs in 2026, with some analysts suggesting that capital is rotating from sectors with stretched valuations, such as technology and AI, into healthcare.
Founded in 2024, Braveheart has previously raised approximately $185 million in Series A financing from a syndicate of prominent investors. Its key backers include Andreessen Horowitz, Forbion, and OrbiMed.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.